FDA authorizes ClonoSEQ assay, a next generation sequencing (NGS) test for minimal residual disease
FDA Approved for Maintenance: Lenalidomide (Revlimid)
FDA Approved for RRMM: Daratumumab + Pomalidomide & Dexamethasone
FDA approves Carfilzomib in combination with Dex or with Lenalidomide and Dex in replased Myeloma
FDA Approved for RRMM: Daratumumab + Revlimid & Dex AND Daratumumab + Velcade & Dex
FDA Approved for RRMM: Elotuzumab (Empliciti) with lenalidomide and dexamethasone (Rd)
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib (Velcade) and Dexamethasone
FDA Approved for RRMM: Kyprolis (carfilzomib) + Revlimid (lenalidomide) and Dexamethasone (KRd)
FDA Approved for RRMM: Daratumumab (Darzalex)
FDA Approved for NDMM: Lenalidomide (Revlimid)
FDA Approved for RRMM: Pomalidomide (Pomalyst) + Dexamethasone
FDA Approved for RRMM: Pomalidomide (Pomalyst)
FDA Approved for RRMM: Carfilzomib (PX-171-003-A1) for relapsed refractory multiple myeloma
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341) VELCADE SUBCUTANEOUSLY
FDA Approved for RRMM: Lenalidomide (Revlimid)
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341)